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Abstract
Background: Duchenne muscular dystrophy (DMD), which afflicts 1 in 3500 boys, is one of the most common genetic
disorders of children. This fatal degenerative condition is caused by an absence or deficiency of dystrophin in striated
muscle. Most affected patients have inherited or spontaneous deletions in the dystrophin gene that disrupt the reading
frame resulting in unstable truncated products. For these patients, restoration of the reading frame via antisense
oligonucleotide-mediated exon skipping is a promising therapeutic approach. The major DMD deletion ‘‘hot spot’’ is found
between exons 45 and 53, and skipping exon 51 in particular is predicted to ameliorate the dystrophic phenotype in the
greatest number of patients. Currently the mdx mouse is the most widely used animal model of DMD, although its mild
phenotype limits its suitability in clinical trials. The Golden Retriever muscular dystrophy (GRMD) model has a severe
phenotype, but due to its large size, is expensive to use. Both these models have mutations in regions of the dystrophin
gene distant from the commonly mutated DMD ‘‘hot spot’’.
Methodology/Principal Findings: Here we describe the severe phenotype, histopathological findings, and molecular
analysis of Cavalier King Charles Spaniels with dystrophin-deficient muscular dystrophy (CKCS-MD). The dogs harbour a
missense mutation in the 59 donor splice site of exon 50 that results in deletion of exon 50 in mRNA transcripts and a
predicted premature truncation of the translated protein. Antisense oligonucleotide-mediated skipping of exon 51 in
cultured myoblasts from an affected dog restored the reading frame and protein expression.
Conclusions/Significance: Given the small size of the breed, the amiable temperament and the nature of the mutation, we
propose that CKCS-MD is a valuable new model for clinical trials of antisense oligonucleotide-induced exon skipping and
other therapeutic approaches for DMD.
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Introduction
The X-linked condition, Duchenne Muscular Dystrophy
(DMD), is one of the most common genetic disorders affecting
children and young adults. This severe, debilitating and ultimately
fatal disease afflicts 1 in 3500 boys. Affected boys are usually
wheelchair-bound by their teenage years and death occurs, as a
result of respiratory failure or cardiomyopathy, in the late teens or
twenties [1]. The disorder results in a progressive degeneration of
muscle fibres due to mutations in the gene that encodes the protein
dystrophin [2,3].
Dystrophin is an integral structural component of skeletal and
cardiac muscles and connects the contractile apparatus to the
sarcolemma. Dystrophin and its associated glycoproteins are
believed to provide mechanical stability during muscle contrac-
tion; hence its deficiency is postulated to result in fragility of the
sarcolemma and subsequently necrosis and, in later stages,
replacement of muscle by fibrous tissue. The pathophysiology is
not completely understood and alternative pathophysiological
mechanisms have been implicated, including alterations in cell
signalling, vascular adaptation, inflammatory responses and repair
mechanisms [4–6].
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The dystrophin gene is one of the largest in the human genome
(approximately 2.5 million base pairs, encoding 79 exons) and
many thousands of mutations are recorded [7]. However, 70% of
DMD patients harbour dystrophin gene deletions in a mutation
rich area or ‘‘hot-spot’’ in the central genomic region (exons 45–
53) [8–10]. The dystrophin-deficiency phenotype varies from a
severe Duchenne-type to the milder allelic form known as Becker
muscular dystrophy (BMD), determined in part by the location of
the mutation in relation to the actin and dystroglycan binding
domains and, in particular, by the mutation’s effect on the reading
frame [7]. Mutations that result in premature truncation (for
example when a frame shift is induced by an exon deletion)
typically result in the severe Duchenne phenotype because no
functional dystrophin is produced. Restoration of the reading
frame through the use of targeted exon skipping (mediated by
antisense oligonucleotides), can generate a functional (but shorter)
dystrophin molecule and is a promising area of genetic therapy
research [11–13]. Indeed, over 90% of human DMD genetic
defects are predicted to be amenable to reading frame correction
by skipping one or more exons [11,14]. Skipping one exon in
particular (exon 51) is predicted to be suitable for more patients
than with any other [11,12,15]. Although clinical trials for
skipping exon 51 in humans are ongoing, novel antisense
chemistries are continuously being developed and methods for
refining and optimizing best target selection are urgently needed.
Several animal models are utilised in DMD research. These
include the mdx mouse, cats with hypertrophic muscular dystrophy,
Golden Retriever muscular dystrophy (GRMD) and German Short
Haired Pointer muscular dystrophy [12,16–18]. The GRMDmodel
in particular is widely used, as clinically and histopathologically
these dogs generally have a severe phenotype that resembles human
DMD; their use in trials of stem cell based therapies [19] and in
exon-skipping therapy [20] has been encouraging. Unfortunately
the Golden Retriever’s large size (approximately 25–30 kg) has
implications for treatment costs in therapeutic trials; furthermore,
handling these large dogs has substantial welfare implications (and
high associated costs) due to their debilitating condition. To reduce
these issues, the same mutation was bred into a colony of beagles to
establish Canine X-linked Muscular Dystrophy in Japan (CXMDJ)
[21] which subsequently has been used to demonstrate efficacy of
exon skipping therapy [22].
Each of the animal models used in DMD research has
associated benefits and disadvantages, but none harbours a
mutation in the region of the dystrophin gene that is most
commonly mutated in human DMD. New canine models of DMD
with different mutations would therefore significantly compliment
research, particularly therapeutic trials. Here we describe a
spontaneous canine model of DMD in the Cavalier King Charles
Spaniel (CKCS), a toy breed, specifically bred for its small size (5–
8 kg) and amiable temperament. In this manuscript we report the
clinical, pathological and molecular characterisation of the model
and investigate the suitability of exon skipping-mediated therapy.
Results
Dogs with CKCS-MD Have a Severe Dystrophic
Phenotype Similar to DMD
The index case was a 10-month-old male neutered client-owned
CKCS from the United Kingdom that was presented to the Royal
Veterinary College for investigation of a generalised neuromuscular
disorder. The dog had been in the owners’ possession from 2months
of age and the puppy had always been of small stature, poorly
muscled and exercise intolerant; the main presenting complaint,
however, was a 3 month progressive history of dysphagia.
On examination the dog was tetraparetic with low body
condition score (2/9; weight = 4.7 kg) (figure 1A), reduced
withdrawal reflexes, macroglossia and restricted jaw movement.
Investigations documented a marked elevation in serum creatine
kinase (CK) activity (33,695 U/l; normal range 61–394 U/l).
Electromyography revealed a myopathic picture with associated
spontaneous activity (complex repetitive discharges and pseudo-
myotonia). Thoracic radiography revealed a normal size and
shape to the cardiac silhouette. The dog was diagnosed with
dystrophin deficient muscular dystrophy (see below). Clinical signs
progressed and euthanasia was performed at the owners’ request
at 24 months of age due to progressive dysphagia and recurrent
aspiration pneumonia.
Two additional young male CKCS from the USA were also
diagnosed with dystrophin deficient muscular dystrophy (dogs 2
and 3). Dog 2 was a 6-month-old intact male that was presented to
a general veterinarian because of dysphagia and decreased range
of jaw motion, first noted by the owner at 2 months of age. A
marked elevation in serum CK activity (64,918 U/L) was
measured. Dog 3 was an 8-month-old neutered male that was
presented to the Veterinary Teaching Hospital, University of
California, Davis, with a history of gagging when eating and
drinking since acquired as a 6-week-old puppy, combined with
exercise intolerance. On physical examination, restricted jaw
mobility and macroglossia were noted. The serum CK activity was
markedly elevated (58,508 U/L). Thoracic radiography revealed a
normal shape and size to the cardiac silhouette and echocardiog-
raphy revealed very mild mitral and tricuspid regurgitation
(believed to be clinically irrelevant) and normal left ventricular
function. Electromyography revealed spontaneous repetitive
discharges and pseudomyotonia in all muscles examined.
Histopathology
Open muscle biopsies were obtained from all 3 dogs under
general anesthesia. The cranial tibial muscle was sampled for the
index case, and the vastus lateralis and triceps muscles for dogs 2
and 3. A dystrophic phenotype was present in all muscle biopsy
specimens (figures 1B and 1C). Excessive variability in myofiber
size was evident with a pattern of degeneration (multifocal groups
of necrotic fibers with variable phagocytosis) and regeneration
(multifocal groups of small calibre fibers with a basophilic
appearance and of histochemical type 2C). Rare calcified deposits
were also observed.
Cardiac Pathology
The heart from dog 1 was of normal size (weighing 35 g) and
was structurally normal with a left-dominant coronary circulation.
There was good preservation of myocyte structure with no
myofibrillary disarray, myocyte hypertrophy, vacuolation or
attenuation. Occasional myocytes in both ventricles showed
hypereosinophilia and loss of myofibril structure without associ-
ated inflammation (changes regarded as agonal rather than
representing intrinsic myocyte pathology). There was no increase
in stromal fibrous tissue apart from focal fibrosis in a papillary
muscle adjacent to an area of endocardial fibroelastosis. Papillary
muscle vessels showed some medial hypertrophy. The above
pathological changes (not shown) were regarded as non-specific.
Evaluation of Dystrophin and Dystrophin Associated
Proteins in CKCS-MD
Dystrophin was absent in skeletal muscle from all dogs (detected
by immunohistochemistry using antibodies to both the dystrophin
rod domain and C terminus; figure 1D) apart from occasional
Novel Canine Model of DMD
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scattered positive revertant fibres (figure 1D). Dystrophin was
similarly absent in both skeletal and cardiac muscle of dog 1 by
immunoblot (figures 1E and 1F). Abundant expression of
developmental myosin heavy chain in muscle from dog 2,
confirmed regeneration (figure 1D). Utrophin expression was
examined in muscle from dog 2 and found to be over-expressed
and relocalised to the sarcolemma in both regenerating and non-
regenerating fibres (figure 1D). As in DMD, in muscle from dog 1
there was reduced expression of b-dystroglycan (figure 1D) and c-
sarcoglycan and sarcoplasmic redistribution of neuronal nitric
oxide synthase (not shown) [23].
Molecular Analysis
RNA was extracted from frozen skeletal muscle and cDNA
synthesised by reverse transcription. PCR primers were used to
amplify overlapping regions of dystrophin cDNA of 1000–1500
base pairs in length for comparison of cDNA from the index case
and a control dog. No difference in fragment sizes between the
affected and control dog PCR products could be appreciated
(results not shown). Primers were then designed to amplify via
PCRs, overlapping regions of 500–600 base pairs suitable for
sequencing, concentrating initially on the central region of the
gene. Of these, PCR with one primer pair (2-10F–2-10R (table S1)
generated a shorter product from dog 1’s cDNA in comparison
with cDNA from a control dog (figure 2A) that upon sequencing
was determined to be due to a deletion of the 109 bp in exon 50
(figure 2B). The deletion results in a frame shift and a premature
stop codon 24 base pairs into exon 51.
Genomic DNA was subsequently used as the template to
amplify by PCR, a 635 bp fragment that included exon 50 and
intronic splice sites in introns 49 and 50 (primer pair 3-1 (table S1).
Sequencing confirmed a splice mutation (G–T) in the 59 consensus
donor splice site within intron 50 in the genomic DNA from dog 1
that was absent in DNA from a control dog and the canine
Figure 1. CKCS-MD phenotype. (A) Photograph of the index case at 10 months of age. Note the generalised muscle atrophy and the low head
carriage, indicative of paresis. (B and C) Representative cryosections of the vastus lateralis muscle from a dystrophic CKCS dog (dog 2) showing excessive
variability in myofiber size and typical areas of degeneration (necrosis and phagocytosis, B) and regeneration (small fibers with prominent vesicular
central nuclei, C). H&E stain, bar = 100 mm for both B and C. (D) Immunohistochemistry of CKCS-MD skeletal muscle (left column) compared with control
dog muscle (right column), labeled with antibodies to the dystrophin rod (Dys1) and carboxy (Dys2) domains, utrophin, developmental myosin heavy
chain (dMHC) and b-dystroglycan (bDGC). Note the absence of expression of dystrophin (with the exception of occasional revertant fibers), redistribution
of utrophin to the sarcolemma in both regenerating and non-regenerating fibers, expression of developmental myosin heavy chain and reduced/variable
expression of b-dystroglycan in the affected dog in comparison with control. Bar = 100 mm for all images. The utrophin and developmental myosin heavy
chain labeling is on serial sections. (E and F) Western immunoblot of extracts from skeletal and cardiac muscle from the index case using antibodies to (E)
the dystrophin rod (Dys1) and (F) the carboxy (Dys2) domains in comparison with control muscle. Note the total absence of dystrophin in both skeletal
and cardiac muscle in the affected dog. The positive bands, detected using an antibody to dysferlin, confirm equal protein loading in each lane.
doi:10.1371/journal.pone.0008647.g001
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reference sequence (GenBank NC_006621) (figure 2C); the same
mutation was subsequently identified by direct sequencing
genomic DNA from dog 2.
Restriction Fragment Length Polymorphism Assay
A restriction fragment length polymorphism (RFLP) assay that
differentiates the mutant from the wild type allele using the
restriction enzyme BSTZ17I was subsequently used to demon-
strate the presence of the mutation in dogs 1, 2 and 3 (figure 2D).
The RFLP also identified the carrier status of dog 3’s dam and
absence of the mutation in dog 3’s sire (figure 2D). Screening of an
additional 96 unrelated female CKCS from the UK (192 alleles)
identified no further heterozygous (carrier) females (all dogs had
the wild type sequence) (results not shown).
Figure 2. Genotype of CKCS-MD. (A and B) RT-PCR of mRNA extracted from skeletal muscle from a control dog (2) and the index case (3) using
primer pair 2–10. Lane 1 is a water control. Note the expected amplicon size of 547 bp in the control but a shorter fragment in the affected dog (A)
which upon sequencing was determined to be due to deletion of the 109 bp in exon 50 (B). (C) Direct sequencing of genomic DNA from a control
(wild type) dog and from the index case (CKCS-MD) revealed a G-T missense mutation (highlighted) in the 59 consensus splice site (underlined) in
intron 50. (D) Restriction fragment length polymorphism (RFLP) assay using restriction enzyme BSTZ17I. The splice site mutation in the 59 consensus
splice site of intron 50 in the index case, dog 2 and dog 3 (lanes 1, 2 and 3 respectively) is identified by the fact that mutant DNA remains undigested
(449 bp) whereas wild type DNA is digested into 2 smaller products of 296 and 153 bp. Lane 4 contains restricted PCR products from dog 3’s mother,
confirming her as a carrier. Lane 5 (dog 3’s father) and lane 6 (control dog) contain restricted PCR products that are wild type.
doi:10.1371/journal.pone.0008647.g002
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Antisense Oligonucleotide Induced Exon-Skipping
To demonstrate the potential of antisense oligonucleotide (AO)
mediated skipping to correct the reading frame in mutant
transcripts from the affected animal, we treated cultured myoblasts
from the index case with an exon-internal AO designed to induce
skipping of exon 51 in humans and compared mRNA expression
with untreated myoblasts [15]. RT-PCR of mRNA extracted from
treated and untreated cells revealed the expected sized product
(with absence of exon 50), however in the treated cells, a smaller
sized product was present, compatible with skipping of exon 51
(figure 3). Direct sequencing of both bands confirmed deletion of
exon 50 in the larger band and deletion of both exon 50 and 51 in
the smaller band (figure 3). Western blot analysis of the lysates of
treated myoblasts, in comparison with untreated cells, revealed
restoration of dystrophin protein expression (figure 3).
Discussion
In this study we sought to determine the genetic basis of
dystrophin-deficient muscular dystrophy in 3 CKCS dogs. The
novel splice site mutation of the dystrophin gene that we have
identified in these affected dogs from the UK and the USA occurs
in a region that is most commonly mutated in humans, and gives
rise to a single exon deletion (exon 50) in the dystrophin mRNA.
This generates a frame shift resulting in a predicted premature
truncation of the gene product. Given that all affected animals
have a severe phenotype, analogous to DMD in humans, we
propose that CKCS with this mutation offer a valuable addition to
the existing repertoire of animal models of DMD. Indeed, this new
canine model may be preferable, given the nature and site of the
mutation and the breed’s small size.
Existing models of DMD include the mdx mouse, which has a
nonsense mutation and premature stop codon within exon 23;
however, the clinical and histological phenotype is much less
severe than would be expected in a human patient with an
equivalent mutation. Indeed, these mice have a near normal life
span and mobility, without significant muscle fibrosis or joint
contractures. Other dystrophin-null mice generated by 5 N-ethyl-
N-nitrosurea mutagenesis [18,24,25] are also mildly affected and
maintain a normal muscle regenerative capacity when compared
with human DMD [17,18]. Researchers have therefore increased
the severity of the murine dystrophin-deficiency phenotype by
creating double mutants: either mice lacking both dystrophin and
its paralogue, utrophin, or both dystrophin and MyoD (a
transcription factor important in muscle development and
regeneration) [18,26]. However, despite the obvious benefits of
murine models (including experimental simplicity, small size,
familiarity, ease of husbandry and relative low costs), these
Figure 3. Antisense oligonucleotide mediated skipping of exon 51 restores protein expression. (A) RT-PCR of mRNA extracted from
cultured canine myoblasts derived from the index case in the absence (lane 1) or presence (lane 2) of AVI-4658; lane 3 is a water control. Note the
666 bp product of the unskipped cDNA (upper band) consistent with the deletion of exon 50 (caused by the mutation) and the smaller 433 bp
product consistent with skipping of exon 51. Sequences were confirmed in the extracted products (B). (C) Western immunoblot of protein extracts
from treated (+) and untreated (2) CKCS-MD myoblasts using antibodies to the dystrophin rod (Dys1) and dysferlin (as a loading control)
demonstrating re-expression of dystrophin following exon 51 skipping in treated cells. (D) Sequence alignment of AVI-4658 (above) with part of the
canine exon 51 sequence, demonstrating the mismatches (in red) analogous to the differences between the canine and human sequences.
doi:10.1371/journal.pone.0008647.g003
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differences mean that these animals do not faithfully model the
clinical situation in DMD: therapeutic trials can be hard to assess
in mildly affected mdx mice and are difficult to interpret in double-
mutant mice [18].
Several larger animal models of dystrophin deficiency have
more severe phenotypes, although a variety of limitations remains.
The analogous feline condition (Feline Hypertrophic Muscular
Dystrophy) [27,28] though severe, is phenotypically distinct from
canine and human dystrophinopathies, being characterised by
generalised muscle hypertrophy, exuberant regeneration and
marked calcification [29]. In dogs, spontaneously occurring
distinct genetic defects leading to dystrophin-deficient muscular
dystrophy have been described in the Golden Retriever and
German Short Haired Pointer [16,17,30,31] Schatzberg et al. [16]
described two male German Short Haired Pointer littermates with
a large (.2.4 Mb) deletion of the p21 region of the X-
chromosome that included the dystrophin gene and promoters.
The phenotype of these cases and progression was only briefly
described; however, there was striking heterogeneity–one dog was
severely affected with a high serum CK activity but a full sibling
was relatively mildly affected and had a correspondingly lower CK
activity [16,32].
The GRMD model is caused by a point mutation in the 39
splice site of exon 7 (resulting in exon 7’s deletion and termination
within exon 8) [31]. Several colonies exist worldwide, all
descended from the same founder male [31]. Subsequently, the
same mutation on a beagle background (Canine X-linked
Muscular Dystrophy Japan CXMDj) was established because of
the beagle’s smaller size (10–15 kg) and the breed’s established use
as an experimental animal [21]. The GRMD clinical and
histopathological phenotype resembles DMD: typically elevated
serum CK activity is detectable shortly after birth, weakness is
evident within the first few weeks and joint contractures
significantly impair movement by 6 months. Death from
respiratory or cardiac failure occurs around 18 months of age
[32]. Beagles with the same mutation are reported to have a
milder phenotype [21,33]. Similar to the cases we describe in
CKCS, macroglossia and dysphagia are prominent features of
both GRMD and CXMDj [32,33]. Dogs with dystrophin-deficient
muscular dystrophy (GRMD, CXMDj, CKCS-MD) retain
ambulatory function until fairly late in the disease’s course, unlike
boys with DMD who require wheelchairs relatively early, likely
reflecting the relative differences between quadrupedal versus
bipedal locomotion when adapting to generalised paresis.
The phenotype in both GRMD and CXMDj is variable–from
clinically unaffected dogs [34] to fulminant neonatal disease and
early death [32,33]. Banks and Chamberlain [18] proposed that
variation may result from differences in expression of truncated
dystrophin transcripts [35] that influence dystrophin expression
and its function through the N-terminal actin-binding domain.
Heterogeneity is also well documented in DMD and is attributed
also to environmental and modifying gene effects [36]. Utrophin
expression in particular is believed to be partially protective; the
protein is generally relocalised to the sarcolemma from its normal
adult position at the neuromuscular junction in DMD patient
muscle [37] and its artificial upregulation in mdx mice and in
GRMD is protective [38,39]. Utrophin’s sarcolemmal expression
was demonstrated in the muscle from one of the CKCS dogs in the
current study in some non-regenerating fibres.
DMD models should be well characterised and it is essential to
consider inherent clinical variability when interpreting the results
of therapeutic trials. In this study we report the clinical features of
3 independent client-owned animals that were presented for
veterinary investigation. All affected dogs had a similar clinical
presentation for dysphagia and macroglossia since an early age.
Further, they all had a similar dystrophic phenotype in muscle
biopsy specimens. It is noteworthy, that none of the dogs in the
current study had either clinical or histopathological signs of
cardiac disease, even though dilated cardiomyopathy is a common
feature in DMD [40]. In CXMDj myocardial fibrosis occurs later
and is milder than in GRMD [41,42]: one explanation therefore
for the absence of evidence of cardiac disease in dogs in the
current study may be the length of time required for the genetic
abnormality to be manifested in heart as opposed to skeletal
muscle in this small breed. Further work, ideally utilizing a colony
of CKCS-MD dogs, would enable comprehensive phenotypic
characterization of various organ systems, including the heart.
Furthermore, if the cardiac muscle changes are found to be
comparatively mild in this model, it would provide an opportunity
to evaluate factors contributing to this phenotype.
Over 70% of human dystrophin gene mutations are intragenic
deletions of varying size [7]. The majority occur in the repetitive
central area of the gene (exons 45–53)–designated the major
deletion hot spot [8–10]–because of the gene’s propensity to
undergo recombination in this region [43,44]. For this reason, we
chose to concentrate our search for the causative mutation in this
region of the canine gene, following an early wider screen of the
entire cDNA. In humans, the phenotype depends on the effect of
the deletion on the reading frame, with the more severe Duchenne
phenotype, typically occurring when there is a frame shift that
results in premature truncation [7]. In CKCS-MD, a transition
mutation in intron 50 (the 59 (donor) splice site of exon 50) causes
deletion of exon 50 from the dystrophin mRNA, a frame shift and
premature truncation in exon 51 and a severe phenotype in the
reported dogs. The index case was of unknown pedigree therefore
it has not been possible to confirm the relationship between
affected dogs. Nonetheless, given that we detected the same
mutation in dogs of the same breed from the UK and the USA
and considering the narrow genetic pool of the CKCS breed [45],
it is most likely that affected dogs are all related to a single founder.
The worldwide prevalence of this mutation is currently unknown:
as no carriers were identified in 96 female CKCS from the United
Kingdom the defect may be present at a low level within the breed
in this country.
Observation that frame shift deletions in humans cause DMD,
but that sometimes larger, in frame deletions, have a much milder
Becker phenotype, prompted investigation of one of the more
promising approaches towards genetic therapy: the use of
exogenous targeted antisense oligonucleotides to mediate artificial
splice defects and induce skipping of additional exons in order to
restore the reading frame [11,12]. Production of these shorter, but
likely functional dystrophin molecules occurs naturally in many
patients with DMD, and can be demonstrated immunohistochem-
ically, by the presence of revertant muscle fibres [46–47] as seen in
two of the affected CKCS dogs in this study. Some authors suggest
that natural, albeit low level expression of revertant dystrophin in
humans may prevent any immune response on dystrophin
reexpression induced through gene therapy [18].
Although not all DMD mutations are amenable to antisense
therapy–for example large deletions of the dystrophin gene or
those affecting the cysteine-rich area–researchers estimate that
exon skipping therapy may be applicable in over 90% of DMD
patients [11,14]. In this study, we have demonstrated the
application of antisense therapy to induce skipping of exon 51 in
CKCS-MD and restore dystrophin expression: the identical
approach (skipping the same exon) has the potential to restore
the reading frame and produce functional dystrophin and
improved clinical signs in more DMD patients than with any
Novel Canine Model of DMD
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other site (up to 13% of DMD patients) [11,12,15]. Indeed for the
current study, we utilised a human-adapted exon-internal
antisense oligonucleotide [15] that is undergoing phase I/II
clinical trials in humans (ClinicalTrials.gov NCT00159250 and
NCT00844597) [14]. It is noteworthy that the canine and human
exon 51 sequences targeted by AVI-4658 differ by 2 nucleotides
(figure 3): optimisation of an analogous canine AVI-4658 sequence
may further improve skipping efficiency in this model.
AO-mediated exon skipping was demonstrated in vitro in
GRMD [21] and a recent study demonstrated the efficacy and
safety of systemic delivery in the CXMDj model [22]. The genetic
defect in GRMD and CXMDj models results in deletion of exon
7; however, the length of adjacent exons is such that skipping of
multiple additional exons (6–8 or 6–9) is required to restore the
reading frame [22]. These recent trials in CXMDj utilised very
high and frequent doses of systemically delivered antisense
oligonucleotides; additional work, in particular, improving deliv-
ery, efficacy and reducing dose, frequency and the potential for
toxicity is very important for similar systemic therapeutic trials in
humans. We suggest the CKCS-MD model offers an opportunity
to optimise exon-skipping approaches in a more clinically relevant
region of the dystrophin gene than in either GRMD or CXMDj.
Alternatively, given the established use of beagles as a laboratory
animal and application of exon skipping therapies in this breed, it
may be advantageous to establish the CKCS-MD mutation in a
beagle colony as performed for the GRMD genotype with
CXMDj [21].
In summary, we have described the clinical phenotype and
revealed the genetic cause of dystrophin deficient muscular
dystrophy in a group of CKCS: a deletion in the region of the
dystrophin gene that is most commonly mutated in DMD.
Current evidence suggests that unlike mdx mice and certain other
larger animal models of DMD, the severe DMD-like phenotype in
these dogs means they may prove useful in trials of antisense-
oligonucleotide induced exon skipping and other treatments, such
as stem cell therapy [12,19]. The small size of this breed and its
amiable temperament are additional advantages since costs for
therapeutic trials, maintenance and care would be substantially
lower than in other larger canine models.
Materials and Methods
All clinical and diagnostic veterinary procedures on animals in
this study were performed with informed owner consent by
licensed veterinary surgeons.
Clinical Evaluation
Physical and neurological examinations were performed in a
standard manner. Electromyography and muscle biopsy were
conducted under general anaesthesia. The former included
assessment of tongue and temporal muscles, epaxial muscles, a
selection of appendicular muscles (including flexors and extensors
at various depths) in both pelvic and thoracic limbs using digital
electrodiagnostic equipment (Medelec Synergy, Oxford Instru-
ments). Open muscle biopsy samples were obtained from the
cranial tibial muscle (index case at age 10 months) and from the
triceps and vastus lateralis muscles in dogs 2 and 3 (aged 6 months
and 8 months respectively).
In the index case, immediately post intravenous barbiturate
euthanasia at 24 months, samples (approximately 1 g) of skeletal
muscle and left ventricle were frozen in cryotubes in dry ice before
being stored at 280uC for western immunoblot analysis. The
remainder of the heart was fixed in 10% buffered formalin.
Additional (approximately 1 g) pieces of skeletal muscle from the
affected dog were stored in tissue culture medium (10% foetal calf
serum, Dulbecco Modified Eagle’s Medium, 10 mM L-glutamine
and penicillin-streptomycin) at 4uC for up to 48 hours until culture.
Muscle Biopsy Samples
Immediately following biopsy, skeletal muscle samples were
positioned on cork discs so that the fibres were orientated vertically
and frozen in optimal cooling temperature compound (Tissuetek)
in isopentane that had been precooled in liquid nitrogen [48].
Samples were cryosectioned at 7 mm (for immunohistochemistry)
and 10 mm for other stains and histochemical reactions. Unstained
cryosections were stained or reacted with haematoxylin and eosin,
modified Gomori trichrome, periodic acid schiff, ATPases at
pH 9.8 and 4.3, esterase, NADH-TR, acid phosphatase, alkaline
phosphatase, oil red O and SPA-HRPO by standard methods
[48].
Immunohistochemistry
Immunohistochemistry was performed by incubating 7 mm
skeletal muscle cryosections with primary antibodies (diluted in
0.2 M PBS, pH 7.2) for 1 hour at room temperature. After 3
washes in PBS, biotinylated goat secondary antibodies (1 in 200;
GE Healthcare) were applied for 30 minutes. After a further 3
washes streptavidin Alexa 594 (1 in 2000; Molecular Probes;
Invitrogen) was added for 30 minutes. The primary antibodies
used were (Novocastra) mouse monoclonal antibodies to the
dystrophin rod and carboxy domains (Dys1 (1:2) and Dys 2 (1:20),
anti-b-dystroglycan (1:20, 43DAG/8D5), c-sarcoglycan (1:30;
35DAG/21B5), utrophin (1:20; DRP2) and developmental myosin
heavy chain (1:20; NCL-MHCd) and a rabbit polyclonal antibody
to nNOS (1:50; R20; Santa Cruz).
Heart
The formalin fixed cardiac muscle obtained post-mortem in the
index case was analysed grossly and histologically. For the latter,
targeted sections were taken from the septum and free walls of
both ventricles of a midventricular transverse slice of myocardium.
They were processed routinely to paraffin wax and 4 mm sections
stained with haematoxylin-eosin for cell morphology and Masson
trichrome, Verhoeff elastic-Van Gieson and picrosirius red stains
for connective tissue content.
Western Immunoblot
Western immunoblots using approximately 30 mg of skeletal
and cardiac muscle from a control dog and from the index case,
and from cultured myoblasts, were performed using antibodies to
Dys1 and Dys2 and dysferlin (loading control) (all Novocastra) via
a 6% polyacrylamide gel with a 4% stacking gel using routine
methods described by Arechevala-Gomeza et al [14].
Genotyping
Total RNA was extracted from frozen muscle using the RNeasy
mini kit (Qiagen) and cDNA was synthesised by reverse
transcription (SuperScript III, Invitrogen) with random hexameric
primers according to the manufacturer’s instructions. Genomic
DNA was extracted from EDTA anti-coagulated blood or frozen
muscle using the DNeasy mini kit (Qiagen) according to the
manufacturer’s protocols.
PCR primers designed using Primer3 (version 0.4.0; http://
frodo.wi.mit.edu) were based on the published sequence for canine
dystrophin mRNA (GenBank NM_001003343) or gDNA (Gen-
Bank NC_006621). Initially these were designed to amplify
overlapping sections of the dystrophin cDNA each of 1000–1500
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base pairs in length (cDNA primers 1-1 to 1-12; table S1) in order
to screen for large deletions by comparing product sizes from a
control and CKCS-MD affected dog. A further set of PCR
primers was designed to amplify 500–600 base pair segments
suitable for sequencing (cDNA primers 2-1 to 2-10; table S1).
Genomic DNA containing exon 50 was amplified by PCR using
primer pair 3-1 (table S1). PCRs were performed using AmpliTaq
Gold polymerase (Applied Biosystems) according to the manufac-
turer’s directions. Sequencing was performed using core facilities.
Restriction Fragment Length Polymorphism Assay
Genomic DNA samples from each of the 3 affected dogs, the
parents of dog 3 and from 96 additional female CKCS dogs were
examined. The latter samples were extracted from stored frozen
whole blood in EDTA derived from CKCSs that had been
presented to the Royal Veterinary College for evaluation of
various medical and surgical conditions following owner consent.
DNA was extracted using the 96 well plate procedure (DNeasy 96
kit, Qiagen) according to the manufacturer’s directions. PCR was
conducted as above (primer pair 3-2; table S1) and the 449 bp
fragment purified as above. Products were incubated with
BSTZ17I enzyme (New England Biolabs) according to manufac-
turer’s directions. The mutant sequence was predicted to remain
uncut whereas digestion of PCR products from unaffected dogs
was predicted to result in 2 smaller bands of 296 and 153 bp.
Carrier females were predicted to be identified by the smaller
normal allele bands and full sized mutant product.
Myoblast Culture
Myoblasts were cultured from muscle explants using established
techniques. Skeletal muscle from dog 1 was cut into 1 mm cubes
with a sterile scalpel blade, placed into the centre of 3.5 cm tissue
culture dishes, and maintained in an incubator (37uC and 5%
CO2) within a single drop of growth medium (DMEM (Dulbecco’s
Modified Eagle’s Medium), 10% FBS (fetal bovine serum),
penicillin-streptomycin (1 U/ml and 1 mg/ml, respectively), and
2 mM L-glutamine). After 6 hours, another 2 ml of medium was
added and the culture dishes were returned to the incubator for 2
to 3 days, by which time myoblast-like cells were readily visible
migrating outward from the tissue. Fresh medium was then added
and cultures were maintained for an additional 7 to 10 days until a
confluent bed of myoblast-like cells had been obtained. Aliquots
were stored frozen until used.
Transient Transfection Experiments and Exon Skipping
6-well tissue culture plates were coated with Matrigel (BD
Biosciences) (0.1 mg/ml) for 30 minutes at 37uC and then air dried
in a tissue culture flow cabinet. Primary myoblasts from the index
case were transfected by means of the nucleofection technique
from Amaxa GmbH (Cologne, Germany) using the NucleofectorH
Kit V, according to the manufacturer’s protocol. In brief, 106
myoblasts were trypsinized, washed in PBS and resuspended in
100 ml of solution V containing 300 nM of AVI-4658 ((+66+95
CTCCAACATCAAGGAAGATGGCATTTCTAG); AVI Bio-
Pharma). Immediately, cells were transferred into a cuvette and
pulsed in a Nucleofector II device (Amaxa) using program B-32.
Subsequently, the cells were diluted with 600 mL of prewarmed
growth medium (37uC) and then distributed between the 6 wells of
the plate each containing 1 mL of prewarmed medium. Following
transfection the cells were left to recover overnight at 37uC and
5% CO2. The following day, medium was replaced with
differentiation medium (DMEM containing 2% horse serum,
penicillin-streptomycin (1 U/mL and 1 mg/mL, respectively), and
2 mM L-glutamine. After 3 days of differentiation, two wells from
the 6-well plate were processed for RNA extraction and
subsequent RT-PCR (detailed protocol follows), and the remain-
ing four wells were kept in differentiation medium for another 7
days before analyzing dystrophin expression by western blot
(protocol described in detail above).
RNA was extracted using TriZol (Invitrogen). Aliquots of
400 ng of total RNA were used for RT-PCR analysis (55uC for
35 min) in a 20 ml reaction using C. therm polymerase (Roche) a
specific primer (4-1R; table S1). 3 ml of this reaction were used as
template for a primary PCR performed by 20 cycles of 94uC
(40 s), 60uC (40 s) and 72uC (80 s), with primers 4-1F and 4-1R
(table S1). 1.5 ml of this reaction was later used as template for a
nested PCR using primers 4-2F and 4-2R, consisting of 30 cycles
of 94uC (40 s), 60uC (40 s) and 72uC (80 s). PCR products were
analyzed on 1.5% agarose gels in Tris-acetate/EDTA (TAE)
buffer, extracted and sequenced as detailed above.
Supporting Information
Table S1 Table S1 Primer pairs used to amplify overlapping
regions of cDNA from the index case (1-1 to 1-12 and 2-1 to 2-10),
genomic DNA to demonstrate the mutation (3-1) and for the
RFLP (3-2) and nested primer pairs for the exon skipping (4-1 and
4-2). For primer pair 4-2, a 666 bp product (in parentheses) is the
size of the product expected with deletion of exon 50 due to the
underlying mutation.
Found at: doi:10.1371/journal.pone.0008647.s001 (0.04 MB
DOC)
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